TrialBlood cancer journal2024

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

A Medina-Herrera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.